BioCity Nottingham based Sygnature Discovery, the leading provider of integrated drug discovery services, has received a significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co. Financial details have not been disclosed. Sygnature is a world-class provider of outsourced...
BioCity Nottingham based Sygnature Discovery has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving...
Integrated drug discovery and pre-clinical solutions provider, Sygnature Discovery, has appointed Dr. David Lustig to the role of Vice President Business Development - United States. Dr. Lustig will play a crucial role in the company’s US expansion, following the opening of Sygnature’s second US office...
BioCity based Sygnature Discovery, a world-leading integrated drug discovery and non-clinical solutions provider, has begun expanding into new state of the art laboratories at Bruntwood SciTech’s Alderley Park, Cheshire, adding Chemistry and Biology expertise to its DMPK and Translational Oncology teams already present on the...
BioCity, Nottingham based Sygnature Discovery, a world-leading integrated discovery and non-clinical solutions provider based in the UK, has joined forces with Altasciences, a CRO/CDMO in the U.S. and Canada specializing in a flexible, innovative approach to comprehensive early stage drug development, to deliver a series...
Sygnature invests in new capabilities at two of its laboratories. • Automated sample storage for multi-customer, multi-year storage HTS relationships • Flow cytometry at Alderley Park to support ex vivo and in vivo tumour analysis BioCity based Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical...
Over 190 individuals from across the Healthcare and Life Sciences sector came together online, on Thursday 8 October to celebrate success at the Medilink UK National Awards. The awards recognised a multitude of achievements and outstanding contributions to the Life Sciences industry, and five companies from...
XenoGesis has been acquired by leading drug discovery CRO, Sygnature Discovery, strengthening the combined DMPK offering and enhancing existing capabilities and expertise. This latest acquisition by Sygnature serves to meet the increasing demand for DMPK services and boosts the company’s reach into the pre-clinical space. XenoGesis’ novel...
BioCity, Nottingham based Sygnature Discovery, a world-leading integrated discovery and pre-clinical solutions provider, has appointed Dr Andy Mead as Director and Head of Drug Abuse and Substance Use Disorders at its integrated in vivo pharmacology company, RenaSci. With 25 years’ experience in the science of...
Great news, at BioCity based Sygnature Discovery we’re further strengthening our oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for cancer drug discovery. The acquisition will add significant in-house expertise at Sygnature in...